Restarting Sertraline for GAD and Depression
Yes, you can restart sertraline now for your patient with a history of GAD and depression who was previously taking it, as sertraline is a first-line, FDA-approved treatment for both conditions with established efficacy and safety. 1, 2
Key Considerations Before Restarting
Verify Safety Parameters
Before reinitiating sertraline, confirm the patient is not:
- Taking MAOIs (requires 2-week washout period) 1
- Taking pimozide (contraindicated due to cardiac risks) 1
- On multiple serotonergic medications that could precipitate serotonin syndrome 3
- Pregnant or breastfeeding without discussing risks/benefits 1
Review Previous Treatment History
Determine why sertraline was discontinued previously:
- If stopped due to side effects: Consider whether those side effects are still a concern or if alternative agents might be preferable 3
- If stopped after successful treatment: The patient may have good response again, as sertraline has demonstrated efficacy in preventing recurrence 4
- If stopped prematurely after first prescription: Note that 28% of patients discontinue after one prescription, and only 24% restart within 9 months 5
Dosing Strategy
Starting Dose
- Begin with 25-50 mg daily 6, 1
- Consider starting at subtherapeutic dose as a "test dose" since initial adverse effects can include anxiety or agitation 3
Titration Schedule
- Increase dose in smallest available increments at 1-2 week intervals as tolerated 3
- Target therapeutic range: 50-200 mg daily 6, 1
- For GAD specifically, sertraline, escitalopram, and paroxetine are considered first-line SSRIs 7, 8
Duration of Treatment
- Acute phase: Minimum 4-6 weeks to assess response 9
- Continuation phase: At least 4-6 months after achieving remission for first episode 6
- Maintenance phase: For recurrent depression/anxiety, consider longer-term treatment as sertraline significantly reduces recurrence risk (6% vs 23% with placebo over 76 weeks) 4
Monitoring Requirements
Initial Monitoring (First 24-48 Hours)
- Watch for signs of serotonin syndrome, especially if patient is on other serotonergic medications 3
- Monitor for behavioral activation, agitation, or worsening anxiety 3, 1
Ongoing Monitoring
- Suicidality: Close monitoring during initial months and after dose changes, particularly in patients under age 25 1
- Blood pressure: Check periodically, as sertraline can cause small increases 3
- Sodium levels: Especially in elderly patients who are at higher risk for hyponatremia 3
- Response assessment: Use standardized rating scales to track symptom improvement 3
Expected Outcomes
Efficacy
- Treatment response (≥50% symptom reduction): Number needed to treat = 7 compared to placebo 8
- Sertraline is effective for both GAD and depression with high-certainty evidence 2, 8
- Onset of symptom relief typically occurs within 2-4 weeks 10
Tolerability
- Overall acceptability: No difference compared to placebo in dropout rates 8
- Common side effects: Nausea, diarrhea, insomnia, sexual dysfunction, increased sweating 1
- Discontinuation due to adverse effects: NNTH = 17 8
Important Warnings
Discontinuation Syndrome Risk
Sertraline is associated with discontinuation syndrome (though less than paroxetine) 3. If stopping treatment in the future, taper gradually rather than abrupt cessation 11.
Drug Interactions
- Sertraline may interact with drugs metabolized by CYP2D6 3
- Avoid NSAIDs, aspirin, or anticoagulants due to increased bleeding risk 3, 1
- Exercise caution with other medications that prolong QT interval 3
Combination Therapy Consideration
For pediatric/adolescent anxiety (ages 6-18), combination treatment with CBT plus sertraline shows superior outcomes compared to monotherapy 3. Consider referral for psychotherapy alongside medication 9.